HomeProductsBioactive CompoundsAnti-Infective AgentsAntibacterial AgentsReltecimod
Chemical structure of CAS 1447799-33-8

Reltecimod

CAS No.1447799-33-8
MDL No.N/A
MFC46H72N10O15S
MW1037.20
InChI KeyVRNHFZYMPDKTBS-WYUJEMNCSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1447799-33-8
Product NameReltecimod

Associated Conditions

infection
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI): Results of a Multicenter, Phase 3 Randomized Controlled Trial of Reltecimod (AB 103).

Annals of surgery • Vol. 272, Issue 3 • 2020
PMID: 32657946DOI: 10.1097/SLA.0000000000004102

A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial.

JAMA surgery • Vol. 149, Issue 6 • 2014
PMID: 24740134DOI: 10.1001/jamasurg.2013.4841

A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by Streptococcus pyogenes.

The Journal of infectious diseases • Vol. 207, Issue 12 • 2013
PMID: 23493729PMC: PMC3654752DOI: 10.1093/infdis/jit104

Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock.

PLoS biology • Vol. 9, Issue 9 • 2011
PMID: 21931534PMC: PMC3172200DOI: 10.1371/journal.pbio.1001149

Documentation

Similar Products